UK Biobank Study: Highest Physical Activity Levels Cut Cancer Risk by 26% Across 13 Types
A UK Biobank study found that highest physical activity levels reduce risk of 13 cancer types by 26%, based on accelerometer data.
Read More
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Author: Evan Vega
Novo Nordisk’s Oral Wegovy Gains FDA Approval, 25mg Semaglutide Tablet Launches for Weight Management
The FDA approved Novo Nordisk’s 25 mg oral Wegovy semaglutide tablet for adult weight management, launching in January 2026.
Read More
DNA-Based ‘Smart’ Drug Targets Cancer Cells with Precision, Activates Only on Tumor Markers
Researchers developed a DNA-based drug that activates only in cancer cells expressing two tumor markers, improving targeted treatment precision.
Read More
Fasting-Mimicking Diet Provides Real Relief in New Crohn’s Disease Clinical Trial
A Stanford trial found a five-day monthly fasting-mimicking diet improved symptoms and remission in 69% of Crohn’s disease patients.
Read More
Aging Lung Cells Trigger Dangerous Immune Overresponse to Flu and COVID in Older Adults, Study Finds
A UCSF study finds aging lung cells trigger harmful immune overreactions to flu and COVID-19 in older adults, worsening lung damage.
Read More
ASH Highlights PDUFA Dates for Subcutaneous Istuximab in Myeloma, CAR T-Cell Therapy for AML/ALL/MDS
The FDA set an April 23, 2026 PDUFA date for subcutaneous isatuximab in relapsed/refractory multiple myeloma, following positive phase 3 trial results.
Read More
Pope Leo XIV’s Good Friday Cross Procession Spotlights Physical Devotion and Spiritual Wellness
Pope Leo XIV’s decision to carry the full wooden cross through all 14 Stations at Rome’s Colosseum drew renewed attention to the connection between physical acts of religious devotion and spiritual wellness.
Read More
VA Study: Type 2 Diabetes Patients Quitting GLP-1s Face Reversed Weight Loss and Higher Heart Risks
A VA study found type 2 diabetes patients stopping GLP-1 drugs regained weight and faced a 22% rise in cardiovascular risks.
Read More
Denali’s Avlayah Reduces CSF Heparan Sulfate by 91% in Phase 1/2 Trial for MPS II
Denali’s Avlayah reduced cerebrospinal fluid heparan sulfate by 91% in a Phase 1/2 trial for pediatric Hunter syndrome patients.
Read More
January-February 2026 (vaccine recommendations, oral GLP-1 approvals, appropriations bill)
The CDC updated childhood vaccine guidelines, reducing routine immunizations from 17 to 11 diseases and shifting six vaccines to high-risk groups.
Read More